pbsv_8k
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
report (Date of earliest event reported): June 1, 2021
Pharma-Bio Serv, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of incorporation)
|
000-50956
|
20-0653570
|
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
6 Road 696, Dorado, Puerto Rico
|
00646
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
(787) 278-2709
|
|
(Registrant’s telephone number, including area
code)
|
|
|
|
(Former name or former address, if changed since last
report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act: None
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security
Holders.
On June
1, 2021, Pharma-Bio Serv, Inc. (the “Company”) held its
2021 Annual Meeting of Stockholders (the “Annual
Meeting”). Below is a summary of the proposals and
corresponding votes.
Kirk Michel and Dov Perlysky were elected as Class II
directors to serve for a term until the 2024 Annual Meeting of
Stockholders or until their successors are duly elected and
qualified. Kirk Michel and Dov
Perlysky received the following votes:
|
Nominee
|
For
|
Withheld
|
|
Kirk
Michel
|
13,216,386
|
10
|
|
Dov
Perlysky
|
13,216,386
|
10
|
There
were 2,446,428 broker non-votes on this proposal.
The
ratification of the selection of Crowe PR PSC as the Company's
independent certified public accountants for the fiscal year ending
October 31, 2021 received the following votes:
|
For
|
Against
|
Abstain
|
|
15,662,745
|
14
|
65
|
There
were no broker non-votes on this proposal.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
PHARMA-BIO SERV, INC.
|
|
|
|
|
|
|
|
Date: June 2, 2021
|
By:
|
/s/ Pedro J. Lasanta
|
|
|
|
|
Pedro J. Lasanta
|
|
|
|
|
Chief Financial Officer, Vice President
Finance and Administration and Secretary
|
|
|
|
|
|
|